Novavax Stock News

Slow and steady wins the race, right? Well, not when it comes to a finite pandemic. Nearly fifteen months after the first coronavirus vaccine…

The company says it has resolved the manufacturing problems that led to earlier delays, and the FDA is reviewing the shot’s authorization application.

The recommendation is yet to be approved by the DCGI. Pune-based SII had last month sought restricted emergency use of Covovax in adolescents. The WHO in December last year allowed emergency use of SII''s version of US firm Novavax''s Covid-19 vaccine. As of now, only Bharat Biotech''s Covaxin is being used to vaccine those in the age group between 15 and 18.

Investors aren't convinced the biotech has a solid, long-term outlook.

Investors aren''t convinced the biotech has a solid, long-term outlook.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips NVAX stock continues to languish for want of evidence for a sustainable fundamental improvement. The 2022 revenue guidance issued by the company did stir some optimism, but investors have quickly fallen back to their guarded stance. The post Novavax Revenue Guidance Does Little to Change Neutral Stance on the Stock appeared first on InvestorPlace . More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Novavax Inc. (NASDAQ:NVAX)’s traded shares stood at 0.74 million during the latest session, with the company’s beta value hitting 1.42. At the last check today, the stock’s price was $78.69, to imply a decrease of -2.29% or -$1.84 in intraday trading. The NVAX share’s 52-week high remains $277.80, putting it -253.03% down since that peak … Novavax Inc. (NASDAQ: NVAX) Stocks Fall -43.71% YTD; What Next For It? Read More »

Serum Institute has been developing Covovax through a technology transfer protocol from Novavax, already approved by the European medicines Agency for conditional marketing authorisation.

Both companies are predicting billions of dollars in vaccine revenue.

Both companies are predicting billions of dollars in vaccine revenue.

The first doses of the Novavax Covid-19 vaccine have already arrived in Spain On the evening of Tuesday, March 1, the very first shipment of the new American Novavax Covid-19 vaccine arrived in Spain. As reported by the Ministry of Health, Spain received nearly 800,000 doses as its share of the European Union’s quota. This […] The post Novavax Covid-19 vaccine arrives in Spain appeared first on Euro Weekly News .

Pfizer (PFE) is developing an RSV vaccine candidate, RSVpreF, to immunize pregnant women or older adults. The FDA grants a breakthrough therapy tag for the candidate's use in pregnant women.

It's all about the coronavirus vaccine of tomorrow.

It''s all about the coronavirus vaccine of tomorrow.